Answers are grounded in this paper and cite their sources.
We performed a 15 year neuropathology follow up of patients in the first trial of Aβ immunotherapy for Alzheimer’s disease (AD). Here we explore the topographical distribution of Aβ removal in the cerebral neocortex allowing comparison with PET amyloid imaging of living subjects as used in current trials. 21 participants of a clinical trial of active immunisation with Aβ42 plus adjuvant (AN1792, Elan Pharmaceuticals) or placebo were studied. Comprehensive neuropathological assessments were performed ranging from 4 months to 14 years after the trial. Large coronal paraffin sections of cerebral hemisphere were immunostained for Aβ, scanned, then (i) the entire neocortical ribbon was scored for plaques in a CERAD-like manner (frequent=3, moderate=2, sparse=1, none=0) and (ii) false coloured to permit visualisation of staining patterns at low power. 16/21 had a distribution of tangles and at least some residual Aβ pathology indicating the cause of dementia had been AD, whereas 5/21 had alternative causes for dementia (PSP=1, DLB=1, VaD=1and FTD-TDP43=2). 18/21 had received the active agent and 3/21 the placebo. Scanning and false colouration of large Aβ immunostained sections generated images suitable for comparison with amyloid PET scans as used in current immunotherapy trials. 13/15 AD subjects receiving the active agent had evidence of plaque removal (almost complete removal=5, extensive patches of removal=4, small patches of removal=4, no plaque removal=2). In the immunised AD group the mean plaque score was 1.46 (range=0.05-2.9) vs. 2.4 for the single placebo AD case. There was a significant inverse correlation between peripheral blood anti-Aβ titres and plaque scores. AD patients actively immunised against Aβ can remain virtually plaque–free for up to 14 years. Nearly a quarter of the patients examined in this study did not have neuropathologically verified AD. Neuropathology follow up of patients in therapeutic trials for AD provides valuable information on the cause of dementia and effects of treatment.
No takes yet. Share an insight, caveat, or question.
Nicoll et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: